RayThera Inc.

RayThera Inc. is a biotechnology company specializing in innovative small molecule therapies aimed at meeting critical needs in immunology, enhancing patient care through advancements in drug discovery. RayThera Inc. , founded in 2023, is focused on developing novel therapies for immunological conditions.

The company is headquartered in San Diego, US, and has completed a total of 1 deal to date. The latest funding round was a Series A, raising USD 110. 000 mn on April 4, 2025, with participation from Foresite Capital, OrbiMed Advisors, and Together To Miracle Capital. The founder's background is currently not specified.

RayThera focuses on advancing drug discovery by developing innovative small molecule therapies specifically designed to address critical unmet needs in the field of immunology. The company's primary offerings include transformative therapies that leverage decades of expertise in drug development. These solutions are tailored to improve patient outcomes by targeting specific immunological conditions that currently lack effective treatment options. The end users of RayThera's products are primarily healthcare providers and patients suffering from these conditions.

RayThera's products are positioned in various international markets, aiming to reach a global audience seeking advanced therapeutic alternatives, although specific geographic locations and market entries are not disclosed. RayThera generates revenue through strategic partnerships and collaborations within the pharmaceutical sector, aligning with healthcare providers and research institutions that facilitate the adoption of their innovative therapies. The company utilizes a direct-to-business model, which allows for tailored agreements based on the specific needs of their partners. Transactions typically revolve around partnership agreements that delineate the rights and responsibilities associated with the development and distribution of RayThera's proprietary therapies.

While detailed pricing plans for specific products or services are not disclosed, the structure of these agreements is designed to support the long-term sustainability of both RayThera and its partners in the biotech ecosystem. In April 2025, RayThera Inc. raised USD 110. 000 mn in Series A funding, co-led by new investors Foresite Capital and OrbiMed Advisors, with participation from another new investor Together To Miracle Capital.

The company will utilize this funding to advance its preclinical immunology pipeline and progress its lead drug candidates through Phase One clinical studies. Future growth initiatives include the design and launch of new products aimed at addressing specific immunological needs, with plans to enter new markets, which will be detailed upon further strategy development.